Search Results - "Mekan, S."

Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis by McDermott, D.F., Rini, B.I., Motzer, R.J., Tannir, N.M., Escudier, B., Kollmannsberger, C.K., Hammers, H.J., Porta, C., George, S., Donskov, F., Gurney, H.P., Grimm, M.-O., Harrison, M., Hutson, T.E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A., Powles, T.

Get full text

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 by Rini, B.I., Tannir, N.M., Escudier, B., McDermott, D.F., Grimm, M.-O., Porta, C., Powles, T., Kollmannsberger, C.K., Gurney, H.P., Tykodi, S.S., Harrison, M., Heng, D.Y.C., Grünwald, V., Choueiri, T.K., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J., George, S.

Get full text

Extra temporal involvement in herpes simplex encephalitis by Wasay, M., Mekan, S. F., Khelaeni, B., Saeed, Z., Hassan, A., Cheema, Z., Bakshi, R.

“…Temporal lobe abnormalities on brain imaging have been described as strong evidence for herpes simplex encephalitis (HSE) in appropriate clinical settings…”
Get full text

Angiotensin converting enzyme (ACE) gene polymorphisms and lupus disease severity: a promising link by Saeed, M, Mekan, S F, Rabbani, M A, Arain, F M, Arif, M, Shaharyar, S

“…Informed consent was taken from all participants and international guidelines for sample collection were followed. 6 All patients fulfilled the American…”
Get full text

Invasive aspergillosis with polyarthritis by Mekan, S. F., Saeed, O., Khan, J. A.

“…Summary We report a case of septic arthritis of multiple joints in an 18‐year‐old male caused by Aspergillus fumigatus. His initial presentation was of…”
Get full text

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma by Motzer, Robert J, Tannir, Nizar M, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Choueiri, Toni K, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, George, Saby, Powles, Thomas, Donskov, Frede, Neiman, Victoria, Kollmannsberger, Christian K, Salman, Pamela, Gurney, Howard, Hawkins, Robert, Ravaud, Alain, Grimm, Marc-Oliver, Bracarda, Sergio, Barrios, Carlos H, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Chen, Allen C, Mekan, Sabeen, McHenry, M. Brent, Wind-Rotolo, Megan, Doan, Justin, Sharma, Padmanee, Hammers, Hans J, Escudier, Bernard

“…In a randomized trial involving previously untreated patients with metastatic intermediate- or poor-risk renal-cell cancer, nivolumab plus ipilimumab was…”
Get full text

Concurrent malaria and enteric fever in Pakistan by Khan, M A, Mekan, S F, Abbas, Z, Smego, Jr, R A

“…The precise incidence of concurrent malaria and enteric fever in most geographical areas is largely unknown, and no data on such an association exists in Asia…”
Get more information

859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial by Michel, L., Jimeno, A., Sukari, A., Beck, T., Chiu, J.W.Y., Ahern, E.S., Hilton, J., A. Hollebecque, Zanetta, S., Patel, J., Mekan, S., Wu, T., Dumbrava, E.E.

Get full text

Cystic breast lymphangioma by Waqar, S N, Khan, H, Mekan, S F, Kayani, N, Raja, A J

Get full text

1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial by Dowlati, A., Cervantes, A., Babu, S., Hamilton, E.P., Wong, S.F., Tazbirkova, A., Sullivan, I.G., Van Marcke de Lummen, C., Italiano, A., Patel, J., Mekan, S., Wu, T., Chiang, A.C.

Get full text

Radiocontrast nephropathy: is it dose related or not? by Mekan, S F, Rabbani, M A, Azhar-uddin, M, Ali, S S

“…To assess the safety of high dose non-ionic contrast media during a single radiological procedure in patients with pre-existing renal impairment. One hundred…”
Get full text

P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer by Raghav, K., Yoshino, T., Taniguchi, H., Tejpar, S., Vogel, A., Wainberg, Z., Yamaguchi, K., Fakih, M., Pedersen, K., Bando, K., Kawakami, H., Beck, J., Kanai, M., Liu, Y., Mekan, S., Pudussery, G., Qiu, Y., Kopetz, S.

Get full text

60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study by Cappuzzo, F., Patel, J., Cho, B.C., Dols, M. Cobo, Cabanillas, R.M. Reyes, Baz, D. Vicente, Pradera, J. Fuentes, Neal, J., Garon, E.B., Mekan, S., Safavi, F., Fernando, N., Chisamore, M., Reck, M.

Get full text

CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups by Escudier, B., Tannir, N.M., McDermott, D.F., Frontera, O.A., Melichar, B., Plimack, E.R., Barthelemy, P., George, S., Neiman, V., Porta, C., Choueiri, T.K., Powles, T., Donskov, F., Salman, P., Kollmannsberger, C.K., Rini, B., Mekan, S., McHenry, M.B., Hammers, H.J., Motzer, R.J.

Get full text

874PTreatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis by McDermott, D F, Rini, B I, Motzer, R J, Tannir, N M, Escudier, B, Kollmannsberger, C K, Hammers, H J, Porta, C, George, S, Donskov, F, Gurney, H P, Grimm, M-O, Harrison, M, Hutson, T E, Doan, J, Yang, S, Rao, S, Mekan, S, Ambavane, A, Powles, T

Get full text

875PCharacterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214 by Rini, B I, Tannir, N M, Escudier, B, McDermott, D F, Grimm, M-O, Porta, C, Powles, T, Kollmannsberger, C K, Gurney, H P, Tykodi, S S, Harrison, M, Heng, D Y C, Grünwald, V, Choueiri, T K, Mekan, S, McHenry, M B, Hammers, H J, Motzer, R J, George, S

Get full text

Trastuzumab for all? A decision analysis examining tradeoffs between efficacy and cardiac toxicity of adjuvant therapy in HER2 positive breast cancer by Gupta, A. K., Mekan, S. F., Eckman, M. H.

“…Abstract only 6022 Background: Early results from three randomized trials showed that adjuvant trastuzumab (T) results in significant reduction in recurrence…”
Get full text

Esophageal cancer at the VA: Does histology matter? by Gupta, A. K., Beg, M. S., Komrokji, R., Atiq, M., Mekan, S., Safa, M.

“…Abstract only 15069 Introduction: In recent years esophageal cancer has shown a shift from largely squamous cell carcinoma (SCC) histology to adenocarcinoma…”
Get full text

Treatment of unresectable or metastatic pancreatic cancer in the VA population: Does it improve survival? by Mekan, S. F., Komrokji, R. S., Beg, M. S., Nahleh, Z. A., Safa, M. M.

“…Abstract only 15121 Background: Locally advanced and metastatic pancreatic adenocarcinoma present as a treatment challenge because of poor outcomes with…”
Get full text

Is hyperglycemia a prognostic factor in pancreatic cancer? by Mekan, S. F., Safa, M. M., Komrokji, R. S., Nahleh, Z. A., Jazieh, A. R.

“…Abstract only 14078 Background: Pancreatic hyperglycemia is one of the manifestations of pancreatic cancer.The purpose of this study is to explore the…”
Get full text